These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9921697)

  • 1. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
    Stahl SM
    J Clin Psychiatry; 1998 Dec; 59(12):642-3. PubMed ID: 9921697
    [No Abstract]   [Full Text] [Related]  

  • 2. [Selective serotonin reuptake inhibitors--current knowledge].
    Dudek D; Zieba A; Siwek M; Wróbel A
    Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Differential features of SSRIs].
    Cervera S
    Rev Med Univ Navarra; 1997; 41(4):245-57. PubMed ID: 10420965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
    Carrasco JL; Sandner C
    Int J Clin Pract; 2005 Dec; 59(12):1428-34. PubMed ID: 16351675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant medication use during breastfeeding.
    Lanza di Scalea T; Wisner KL
    Clin Obstet Gynecol; 2009 Sep; 52(3):483-97. PubMed ID: 19661763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
    Grimsley SR; Jann MW
    Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
    Lam D; Gorman DA; Patten S; Pringsheim T
    Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
    Maurel S; De Vry J; Schreiber R
    Alcohol; 1999 Apr; 17(3):195-201. PubMed ID: 10231167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
    Mochcovitch MD; Nardi AE
    Expert Rev Neurother; 2010 Aug; 10(8):1285-93. PubMed ID: 20662754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay.
    Jacobsen NW; Hansen CH; Nellemann C; Styrishave B; Halling-Sørensen B
    Toxicol In Vitro; 2015 Oct; 29(7):1729-35. PubMed ID: 26162595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
    Dell'Agnello G; Ceravolo R; Nuti A; Bellini G; Piccinni A; D'Avino C; Dell'Osso L; Bonuccelli U
    Clin Neuropharmacol; 2001; 24(4):221-7. PubMed ID: 11479393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin agents in the treatment of acquired brain injury.
    Zafonte RD; Cullen N; Lexell J
    J Head Trauma Rehabil; 2002 Aug; 17(4):322-34. PubMed ID: 12106001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
    Sánchez C; Meier E
    Psychopharmacology (Berl); 1997 Feb; 129(3):197-205. PubMed ID: 9084057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
    Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
    J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line.
    Hansen CH; Larsen LW; Sørensen AM; Halling-Sørensen B; Styrishave B
    Toxicol In Vitro; 2017 Jun; 41():1-11. PubMed ID: 28179152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.